-
Mashup Score: 0Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in 7-year Data - 12 month(s) ago
May 9, 2023 — Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company’s innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards’ bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8
Researchers hope this “offspring” trial design offers a chance to address the entrenched under-enrollment of women in CV trials.
Source: TCTMD.comCategories: Cardiac Surgery, Latest HeadlinesTweet-
RT @arnaldodimagli: Roma-Women: the first-ever cardiac surgery trial in women. #cabg #women #trial https://t.co/WQjWf2jCTx https://t.co/n…
-
-
Mashup Score: 0
With this rising popularization of enhanced recovery after surgery (ERAS) protocols, it is important to ask if the current and developing pathways are fully comprehensive for the patient’s perioperative experience. Many current pathways discuss …
Source: PubMed Central (PMC)Categories: Latest Headlines, PulmonologyTweet-
A #Trial of Adding #Lung #Protective Strategies to Existing Enhanced #Recovery After #Surgery #Protocols and Its Effect on Improving #Postoperative Lung #Function https://t.co/D0GzfzHKL9 https://t.co/m6FrFXeiy2
-
-
Mashup Score: 0
Background Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mechanical ventilation mode that delivers assistance to breathe in proportion to the patient’s effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient’s respiratory effort or workload within a normal range. Short-term and physiological benefits of this…
Source: BioMed CentralCategories: Latest Headlines, PulmonologyTweet-
#Study #protocol for a #randomized #controlled #trial of Proportional Assist #Ventilation for Minimizing the Duration of #Mechanical Ventilation: the PROMIZING study https://t.co/ekBeF2URiW https://t.co/Ewf6ICQ9pE
-
-
Mashup Score: 0
Background: Patient triggered Adaptive Pressure Control (APC-CMV) has been widely adopted as an alternative ventilator mode to patient-triggered Volume control (VC-CMV). However, the comparative effectiveness of the two ventilator modes remain uncertain. Research Question: We sought to explore clinical and implementation factors pertinent to a future definitive RCT assessing APC-CMV vs VC-CMV as…
Categories: Latest Headlines, PulmonologyTweet-
A Pragmatic Pilot #Trial Comparing #Patient Triggered Adaptive Pressure Control to Patient Triggered Volume Control #Ventilation in #Critically #ill Adults https://t.co/jxhtm9Vmyv https://t.co/FMQJPb24E1
-
-
Mashup Score: 0Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure - 1 year(s) ago
March 21, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure (HF) Therapeutics…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @CVRx_Inc CVRx, Inc. announced detailed preliminary results of the post-market phase of the #BeAT_HF #trial at the second annual Technology and Heart Failure (#HF) Therapeutics (#THT) conference: https://t.co/aAd1JnYkPv
-
-
Mashup Score: 0
March 6, 2023 — In findings presented from the STELLAR Phase III Trial during the American College of Cardiology’s 2023 Scientific Session, ACC23/WCC, researchers reported that adding a novel first-in-class medication in combination with background therapy led to significant improvements in walking distance for patients with pulmonary arterial hypertension (PAH), a severe, progressive condition…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @ACCinTouch Significant improvements in six-minute walking distance were reported in the #STELLAR Phase III #Trial whose findings were unveiled during a Featured #ClinicalResearch session at #Acc23: https://t.co/gsKDWEVGLr
-
-
Mashup Score: 0New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE) - 1 year(s) ago
February 23, 2023 — Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @SIRspecialists Few adverse events are connected to the use of #inferior_vena_cava (#IVC) filters to help prevent deep vein #bloodclots from developing into #pulmonary_embolisms (#PE), according to the findings of the #PRESERVE #trial: https://t.co/z1CuDHsjH6
-
-
Mashup Score: 0CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial - 1 year(s) ago
February 22, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced today the preliminary topline results of the BeAT-HF, Baroreflex ActivationTherapy for Heart Failure, post-market randomized clinical trial. …
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @CVRx_Inc The #trial did not meet its primary endpoint, however, the totality of data supports #Barostim’s use as an effective treatment for patients with #heartfailure: https://t.co/gkP07bPjKE
-
-
Mashup Score: 0Renewed calls for fallopian tube removal to avoid ovarian cancer - 1 year(s) ago
There is increasing evidence that most high-grade serous ovarian cancers arise from cells in the fallopian tubes.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Renewed calls for #FallopianTube removal to avoid #OvarianCancer 👉https://t.co/gssuLYFxNq @MDedgeHemOnc #Trial #Detection https://t.co/t5bKJFXHrp
-
@DAICeditor @EdwardsLifesci Edwards Lifesciences announced new data from the #COMMENCE #aortic #trial, demonstrating low rates of structural valve deterioration (#SVD) in #bioprosthetic aortic valves with the company's innovative #RESILIA tissue: https://t.co/QXmtL6KLj8